176 related articles for article (PubMed ID: 20963554)
1. Partial remission of metastatic papillary thyroid carcinoma with sunitinib. Report of a case and review of the literature.
Kaldrymides P; Kostoglou-Athanassiou I; Gkountouvas A; Veniou E; Ziras N
Endocrine; 2010 Feb; 37(1):6-10. PubMed ID: 20963554
[TBL] [Abstract][Full Text] [Related]
2. Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma.
Dawson SJ; Conus NM; Toner GC; Raleigh JM; Hicks RJ; McArthur G; Rischin D
Anticancer Drugs; 2008 Jun; 19(5):547-52. PubMed ID: 18418222
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib therapy in metastatic papillary thyroid cancer.
Gori S; Foglietta J; Rossi M; Hamzaj A; Stocchi L; Galuppo C; Picece V; Puxeddu E; Furlani L
Tumori; 2013; 99(6):285e-7e. PubMed ID: 24503805
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma.
Molina AM; Feldman DR; Ginsberg MS; Kroog G; Tickoo SK; Jia X; Georges M; Patil S; Baum MS; Reuter VE; Motzer RJ
Invest New Drugs; 2012 Feb; 30(1):335-40. PubMed ID: 20711632
[TBL] [Abstract][Full Text] [Related]
5. The emerging role of sunitinib in the treatment of advanced epithelial thyroid cancer: our experience and review of literature.
Pasqualetti G; Ricci S; Dardano A; Ferdeghini M; Del Tacca M; Monzani F
Mini Rev Med Chem; 2011 Aug; 11(9):746-52. PubMed ID: 21707530
[TBL] [Abstract][Full Text] [Related]
6. Activity and Safety of Sunitinib in Patients with Advanced Radioiodine Refractory Thyroid Carcinoma: A Retrospective Analysis of 57 Patients.
Atallah V; Hocquelet A; Do Cao C; Zerdoud S; De La Fouchardiere C; Bardet S; Italiano A; Dierick-Galet A; Leduc N; Bonichon F; Leboulleux S; Godbert Y
Thyroid; 2016 Aug; 26(8):1085-92. PubMed ID: 27370404
[TBL] [Abstract][Full Text] [Related]
7. Off-label use of sunitinib in patients with advanced, epithelial thyroid cancer: a retrospective analysis.
Pasqualetti G; Ricci S; Boni G; Tognini S; Polini A; Mariani G; Ferdeghini M; Monzani F
Recent Pat Endocr Metab Immune Drug Discov; 2012 May; 6(2):171-6. PubMed ID: 22533521
[TBL] [Abstract][Full Text] [Related]
8. Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer.
Fagin JA; Tuttle RM; Pfister DG
J Clin Endocrinol Metab; 2010 Jun; 95(6):2621-4. PubMed ID: 20525911
[No Abstract] [Full Text] [Related]
9. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
Cabanillas ME; Waguespack SG; Bronstein Y; Williams MD; Feng L; Hernandez M; Lopez A; Sherman SI; Busaidy NL
J Clin Endocrinol Metab; 2010 Jun; 95(6):2588-95. PubMed ID: 20392874
[TBL] [Abstract][Full Text] [Related]
10. Targeted molecular therapies in thyroid carcinoma.
Romagnoli S; Moretti S; Voce P; Puxeddu E
Arq Bras Endocrinol Metabol; 2009 Dec; 53(9):1061-73. PubMed ID: 20126863
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib for the treatment of thyroid cancer.
Gómez-Sáez JM
Expert Opin Investig Drugs; 2016 Nov; 25(11):1345-1352. PubMed ID: 27677828
[TBL] [Abstract][Full Text] [Related]
12. Utilization of Sunitinib for Renal Cell Cancer: an Egyptian University hospital experience.
M Eel D
Asian Pac J Cancer Prev; 2016; 17(7):3161-6. PubMed ID: 27509945
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer.
Bikas A; Kundra P; Desale S; Mete M; O'Keefe K; Clark BG; Wray L; Gandhi R; Barett C; Jelinek JS; Wexler JA; Wartofsky L; Burman KD
Eur J Endocrinol; 2016 Mar; 174(3):373-80. PubMed ID: 26671977
[TBL] [Abstract][Full Text] [Related]
14. Activity and safety of sunitinib in patients with advanced radioactive iodine-refractory differentiated thyroid carcinoma in clinical practice.
Díez JJ; Iglesias P; Alonso T; Grande E
Endocrine; 2015 Mar; 48(2):582-8. PubMed ID: 25030550
[TBL] [Abstract][Full Text] [Related]
15. Three cases of sporadic medullary thyroid carcinoma in progression treated with sunitinib.
Currás Freixes M; Díaz Pérez JÁ; Casado Herráez A; Ochagavía Cámara S
Endocrinol Nutr; 2014 Jan; 61(1):62-3. PubMed ID: 24125629
[No Abstract] [Full Text] [Related]
16. Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma.
Sato S; Muraishi K; Tani J; Sasaki Y; Tokubuchi I; Tajiri Y; Yamada K; Suekane S; Miyajima J; Matsuoka K; Hiromatsu Y
Endocr J; 2010; 57(10):873-80. PubMed ID: 20733268
[TBL] [Abstract][Full Text] [Related]
17. Long-term response with sunitinib for metastatic renal cell carcinoma.
Ronnen EA; Kondagunta GV; Ginsberg MS; Russo P; Motzer RJ
Urology; 2006 Sep; 68(3):672.e19-20. PubMed ID: 16979716
[TBL] [Abstract][Full Text] [Related]
18. When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report.
Sbitti Y; Debbagh A; Slimani K; Mahi M; Errihani H; Ichou M
J Med Case Rep; 2018 Mar; 12(1):80. PubMed ID: 29554941
[TBL] [Abstract][Full Text] [Related]
19. Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer.
Lin CI; Whang EE; Lorch JH; Ruan DT
Surgery; 2012 Dec; 152(6):1142-9. PubMed ID: 23158184
[TBL] [Abstract][Full Text] [Related]
20. Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature.
Karaca H; Lale A; Dikilitas M; Ozkan M; Er O
Med Oncol; 2010 Sep; 27(3):1023-6. PubMed ID: 19830602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
